Indication for CycloSam®
Bone Marrow Ablation
Bone Marrow Ablation
Certain cancers, immune system diseases, blood diseases, and sickle cell disease require bone marrow ablation/transplantation (BMA/T). The standard protocol for BMA/T consists of high dose chemotherapy and/or Total Body Irradiation (TBI). This standard treatment is physically devastating to patients, especially younger and older patients.
Radiopharmaceuticals are potentially the best option because there may be fewer patient side effects. Many radiopharmaceuticals have excellent safety records. However, current products have long half-lives and high levels of impurities, meaning patients could be immunocompromised for unacceptably long periods of time.
CycloSam® may be able to become the new standard of care. The short half-life (46 hours) and low impurity profile means a patient may be able to be treated and transplanted a few days later.
High Dose Chemotherapy Agents
- Multiple doses over multiple days
- Disrupts the short-term cell production cycle resulting in mucositis
- Damage to soft tissue
- Can take days to be eliminated while side effects can last months
- Cytotoxic
- Multiple contraindications
CycloSam® Sm-153 DOTMP*
✓ One day dosage
✓ Not shown to disrupt short-term cell production
✓ Not shown to damage soft tissue
✓ CycloSam® radiation is directed to the bone and away from soft tissue
✓ Most of the non-bone-bound dose can be eliminated from the body right away
✓Not cytotoxic
✓May be used when chemotherapy is contraindicated
*based on animal and in vitro data to date